Pharmacogenomics Market Size Outlook and Demand Growth Across 2026–2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Pharmacogenomics Market Expected To Change Between 2026 And 2030?

The pharmacogenomics market has experienced substantial expansion in recent times. This market is projected to expand from $9.84 billion in 2025 to $10.85 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this growth has been driven by several factors, including intensified genomic research, the advancement of targeted therapies, an increase in chronic disease prevalence, enhanced sequencing technologies, and wider access to genetic testing services.

The pharmacogenomics market is projected to experience substantial growth in the upcoming years. It is anticipated to achieve a size of $15.98 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.2%. This projected expansion can be linked to several factors, including increased investments in precision medicine programs, the escalating adoption of AI-driven genomic analysis, the broadening application of pharmacogenomics in oncology and cardiology, a heightened emphasis on individualized drug development, and continuous progress in bioinformatics platforms. Significant trends anticipated during this period involve the increasing embrace of personalized medicine approaches, a rising reliance on genetic testing for drug selection, the progressive integration of pharmacogenomic data into clinical workflows, the expansion of companion diagnostics, and an enhanced focus on precision therapeutics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

Which Major Factors Are Driving The Expansion Of The Pharmacogenomics Market?

The expanding prevalence of chronic illnesses is anticipated to boost the pharmacogenomics market’s advancement moving forward. Chronic diseases are long-term medical conditions, frequently lasting a person’s entire life. The increase in chronic conditions stems from the global population’s extended average lifespan and the widespread adoption of behavioral risk factors like inactive lifestyles, unhealthy diets, and tobacco consumption. Pharmacogenomics provides a tailored strategy for managing chronic diseases, considering individual genetic differences that influence how drugs affect patients. As an illustration, for 2025, the International Diabetes Federation, a health organization based in Belgium, reported that in 2024, approximately 589 million adults aged 20-79 were living with diabetes. This figure is predicted to climb to 853 million by 2050, with over 4 in 5 adults affected by diabetes residing in low and middle income countries. Consequently, the rising incidence of chronic diseases is fueling the expansion of the pharmacogenomics market.

How Is The Pharmacogenomics Market Structured Across Different Segments?

The pharmacogenomics market covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Which Trends Are Shaping The Future Of The Pharmacogenomics Market?

Companies operating within the pharmacogenomics market are increasingly prioritizing artificial intelligence (AI) driven models that manage drug-drug interactions (DDIs) at the genomic level, consequently enhancing medication safety, reducing adverse reactions, and enabling highly personalized prescribing. AI-powered pharmacogenetics engines are defined as advanced digital systems that leverage artificial intelligence to analyze a person’s genetic profile and predict their response to specific medications. For example, in December 2024, PGxAI, a US-based artificial intelligence (AI) driven pharmacogenetics company, launched its Sirius model, an AI-powered pharmacogenetics engine designed to personalize drug selection, dosage, and drug-drug interaction management based on an individual’s genome. Sirius encompasses 730 drugs and 40 key pharmacogenes, providing considerably broader coverage than traditional pharmacogenomic solutions. The model is intended for use by hospital systems, diagnostic labs, and clinical research organizations, helping to mitigate adverse reactions and improve therapeutic outcomes.

Which Major Players Dominate The Pharmacogenomics Market?

Major companies operating in the pharmacogenomics market are Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Genomika Diagnósticos

Read the full pharmacogenomics market report here:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

Which Region Currently Holds The Largest Share Of The Pharmacogenomics Market?

North America was the largest region in the pharmacogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pharmacogenomics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7072&type=smp

Browse Through More Reports Similar to the Global Pharmacogenomics Market 2026, By The Business Research Company

Pharma 4 0 Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharma-4-0-global-market-report

Consumer Genomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/consumer-genomics-global-market-report

Pharmaceutical Label Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-label-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795